KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Short-term Investments: 2018-2024

Historic Short-term Investments for Aurinia Pharmaceuticals (AUPH) over the last 6 years, with Dec 2024 value amounting to $275.0 million.

  • Aurinia Pharmaceuticals' Short-term Investments fell 10.59% to $278.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $278.6 million, marking a year-over-year decrease of 10.59%. This contributed to the annual value of $275.0 million for FY2024, which is 8.81% down from last year.
  • According to the latest figures from FY2024, Aurinia Pharmaceuticals' Short-term Investments is $275.0 million, which was down 8.81% from $301.6 million recorded in FY2023.
  • In the past 5 years, Aurinia Pharmaceuticals' Short-term Investments ranged from a high of $301.6 million in FY2023 and a low of $126.0 million during FY2020.
  • For the 3-year period, Aurinia Pharmaceuticals' Short-term Investments averaged around $290.6 million, with its median value being $295.2 million (2022).
  • Its Short-term Investments has fluctuated over the past 5 years, first spiked by 85.89% in 2021, then declined by 8.81% in 2024.
  • Aurinia Pharmaceuticals' Short-term Investments (Yearly) stood at $126.0 million in 2020, then surged by 85.89% to $234.2 million in 2021, then climbed by 26.07% to $295.2 million in 2022, then increased by 2.17% to $301.6 million in 2023, then fell by 8.81% to $275.0 million in 2024.